Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.18 USD
Change Today -0.06 / -0.42%
Volume 94.1K
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

heron therapeutics inc (HRTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $16.49
52 Week Low
10/13/14 - $6.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

heron therapeutics inc (HRTX) Related Businessweek News

No Related Businessweek News Found

heron therapeutics inc (HRTX) Details

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company’s lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.

59 Employees
Last Reported Date: 03/13/15
Founded in 1983

heron therapeutics inc (HRTX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $349.3K
President and Director
Total Annual Compensation: $453.8K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $52.6K
Compensation as of Fiscal Year 2013.

heron therapeutics inc (HRTX) Key Developments

Heron Therapeutics, Inc. Reaches Target Patient Enrollment in MAGIC Phase 3 Study of SUSTOL®

Heron Therapeutics, Inc. announced that it has reached its enrollment target in MAGIC (Modified Absorption Granisetron In the Prevention of Chemotherapy induced nausea and vomiting (CINV)) and is in the process of closing enrollment of new patients at its clinical sites. MAGIC is Heron’s Phase 3 study evaluating the efficacy of SUSTOL® (granisetron injection, extended release) in the prevention of delayed-onset CINV following administration of highly emetogenic chemotherapy (HEC) agents. This prospective, randomized, placebo-controlled, Phase 3 study compares SUSTOL plus the neurokinin-1 (NK1) receptor antagonist fosaprepitant and dexamethasone to the current standard of care for delayed-onset CINV following administration of HEC agents, ondansetron plus fosaprepitant and dexamethasone. The study has enrolled approximately 900 patients receiving various HEC agents, as defined by the 2011 ASCO guidelines, at approximately 200 U.S. sites. The primary endpoint in this study is the proportion of patients who achieved a complete response, defined as no emesis and no rescue medications, in the 24-120 hours following chemotherapy.

Heron Therapeutics, Inc. Announces Positive Results from a Phase 1 Clinical Study of HTX-011

Heron Therapeutics, Inc. announced positive results from a Phase 1 clinical study of HTX-011, Heron's lead product candidate for the prevention of post-operative pain. HTX-011, which utilizes Heron's proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in combination with the anti-inflammatory meloxicam. This placebo-controlled, Phase 1 study evaluated single doses of 100 mg, 200 mg and 400 mg of HTX-011 in healthy volunteers. The key results from the study are described below: The desired pharmacokinetic profile for both bupivacaine and meloxicam was achieved. Specifically, therapeutically relevant drug levels of bupivacaine were sustained for 2-3 days. This was achieved in the absence of the large initial peak of bupivacaine that is observed with commercially available formulations of the drug. Robust anesthetic activity that closely correlated with plasma bupivacaine concentrations was observed, with anesthetic effects persisting through 96 hours. All three doses were well-tolerated with no serious adverse events, clinically relevant ECG or laboratory changes, or premature discontinuations. Mild redness and bruising were seen at some injection sites due to the subcutaneous administration of the product in this healthy volunteer study.

Heron Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Heron Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operation was $19,495,000 compared with $13,831,000 for the same period last year. Net loss was $20,624,000 or $0.71 basic and diluted per share compared with $14,043,000 or $0.75 basic and diluted per share for the same period last year. For the year, the company reported loss from operation was $74,561,000 compared with $54,457,000 for the same period last year. Net loss was $76,367,000 or $2.87 basic and diluted per share compared with $55,283,000 or $3.42 basic and diluted per share for the same period last year. The increase in net loss was primarily due to the ongoing Phase 3 HEC study of SUSTOL, which was initiated in 2014, and expenses related to new product development, including program targeting the management of post-operative pain. The decrease in net loss per share for the three and twelve months ended December 31,2014 compared to the same periods in 2013 was mainly due to the increase in shares outstanding in 2014 as a result of November 2013 and June 2014 common stock offerings, partially offset by the increase in net loss.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HRTX:US $14.18 USD -0.06

HRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $62.26 USD -1.19
Foamix Pharmaceuticals Ltd $10.46 USD -0.44
Johnson & Johnson $101.08 USD +0.62
Pacira Pharmaceuticals Inc/DE $85.07 USD +0.80
Sanofi €95.86 EUR +0.51
View Industry Companies

Industry Analysis


Industry Average

Valuation HRTX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HERON THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at